# A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

> **NCT06527404** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 469 (actual)

## Conditions studied

- Prurigo Nodularis

## Interventions

- **DRUG:** Rocatinlimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06527404
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-18
- **Primary completion:** 2026-04-17
- **Final completion:** 2027-01-17
- **Target enrollment:** 469 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06527404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06527404, "A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06527404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*